Self-Efficacy in Researching and Obtaining Medical Cannabis by Patients With Chronic Conditions

Brady, John P.; Bruce, Douglas; Foster, Elissa; Shattell, Mona

doi:10.1177/1090198120914249

Cited by 13 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, he observed that those patients with higher self-efficacy about medical cannabis were more likely to engage in activities to experiment and incorporate medical cannabis into their medical management despite the perspective of their providers about this treatment modality. 38 These findings may provide a take into our results that 89% of the assessed medical cannabis patients considered that cannabis is better than opioids for their pain management.…”

Section: Discussionmentioning

confidence: 70%

Patient Experience and Perspective on Medical Cannabis as an Alternative for Musculoskeletal Pain Management

et al. 2022

View full text Add to dashboard Cite

Introduction: The current rate of opioid prescription is disquieting because of their high abuse potential, adverse effects, and thousands of overdose deaths. This situation imposes urgency in seeking alternatives for adequate pain management. From this perspective, this study aimed to evaluate the experience and the perceived analgesic efficacy of medical cannabis in managing the pain associated with musculoskeletal conditions. Methods: A 28-question survey was distributed to patients at a major medical cannabis center in Puerto Rico for 2 months. Demographics, medical history, cannabis usage, cannabis use perspective, and analgesic efficacy were assessed in the questionnaire. Results: One hundred eighty-four patients completed our survey. The majority (67%) were males, and the participants' average age was 38 years. This study showed an average pain reduction score of 4.02 points on the Numeric Rating Scale among all the participants. Those with musculoskeletal conditions reported a notable average pain reduction score of 4.47 points. In addition, 89% of the participants considered medical cannabis to be more effective than narcotics for adequate pain management. Conclusions: This study demonstrated that the use of medical cannabis among patients with musculoskeletal conditions effectively reduced pain levels based on their Numeric Rating Scale reported scores.

show abstract

Section: Discussionmentioning

confidence: 70%

Patient Experience and Perspective on Medical Cannabis as an Alternative for Musculoskeletal Pain Management

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Typical use of PDCs for therapeutic intent involves the patient trialing multiple different products and varieties of cannabis indiscriminately. 37 PDCs for medical use may be purchased from unlicensed sellers or obtained from unknown sources through friends and family. 32 We challenge MC service providers to demand that LPs provide a high-quality, reliable product with pharmacokinetic testing and stability data.…”

Section: Discussionmentioning

confidence: 99%

“…36 Studies reveal that patients rely on experimentation with different dosage forms and plant cultivars, seek advice from retail associates or friends, or research online to fuel self-efficacy for the use of MC. 37 Further unearthing this issue, several observational studies suggest that patients do not fully understand the risks of cannabis use. 24,38 An alarming 76% of Canadian MC users reported that they expected no problems when combining cannabis with other medications.…”

Section: Description and Disposition Of Patients With Cancer Accessin...mentioning

confidence: 99%

Description and Disposition of Patients With Cancer Accessing a Novel, Pharmacist-Led Cannabis Consultation Service

Marchese

Zhu

Charbonneau

et al. 2022

JCO Oncology Practice

View full text Add to dashboard Cite

PURPOSE: The Cannabis Consultation Service (CCS) is an innovative pharmacist-led resource at the Sunnybrook Odette Cancer Centre. Its mandate is to provide education and guide patients through access and appropriate use of high-quality plant-derived cannabinoids (PDCs). Our objective was to describe the CCS, explain its processes, and characterize patient disposition with respect to use of PDCs. METHODS: We retrospectively reviewed the charts of patients referred to the CCS from July 13, 2020, to March 05, 2021. We used descriptive statistics to report on the patient population and service metrics. RESULTS: During the 34-week period, 96 patients accessed the CCS (median age, 61 years). The top reasons for CCS consultation were management of cancer pain, insomnia, and general interest. Medical cannabis was supported as an option in 44/96 patients. Reasons for not supporting PDC use included lack of indication, potential drug interaction/contraindication, or requiring treatment with first-line therapy. Of the 40 patients requiring a medical document, 22 initiated therapy. The most common product used was a 2:50 THC:CBD (Tetrahydrocannabinol:Cannabidiol) cannabis oil. At the date of last contact, few patients remained on therapy because of lack of benefit, patient choice, and/or hesitancy. CONCLUSION: Despite patients with cancer having interest in seeking PDCs for symptom management, only a few initiated and continued therapy. Pharmacists have an opportunity to advise patients and the oncology team on the risks and benefits of PDCs. These results can be used to support the development of medical cannabis programs by oncology centers and focus future research priorities.

show abstract

“…Moreover, involving patients in the construction of such studies should also add relevant elements to the analysis. Indeed, directly involving patients in research, in the recruitment or tools development, could help better assess these challenges and facilitators in patients’ self-management [ 20 , 21 ], since they can help identify crucial elements that could have otherwise been overlooked. [ 22 – 24 ].…”

Section: Introductionmentioning

confidence: 99%

Perceptions and engagement of patients with chronic conditions on the use of medical cannabis: a scoping review

Pomey,

Jutras-Aswad,

Paquette

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

Context Studies generally focus on one type of chronic condition and the effect of medical cannabis (MC) on symptoms; little is known about the perceptions and engagement of patients living with chronic conditions regarding the use of MC. Objectives This scoping review aims to explore: (1) what are the dimensions addressed in studies on MC that deal with patients' perceptions of MC? and (2) how have patients been engaged in developing these studies and their methodologies? Through these objectives, we have identified areas for improving future research. Methods We searched five databases and applied exclusion criteria to select relevant articles. A thematic analysis approach was used to identify the main themes: (1) reasons to use, to stop using or not to use MC, (2) effects of MC on patients themselves and empowerment, (3) perspective and knowledge about MC, and (4) discussion with relatives and healthcare professionals. Results Of 53 articles, the main interest when assessing the perceptions of MC is to identify the reasons to use MC (n = 39), while few articles focused on the reasons leading to stop using MC (n = 13). The majority (85%) appraise the effects of MC as perceived by patients. Less than one third assessed patients’ sense of empowerment. Articles determining the beliefs surrounding and knowledge of MC (n = 41) generally addressed the concerns about or the comfort level with respect to using MC. Only six articles assessed patients’ stereotypes regarding cannabis. Concerns about stigma constituted the main topic while assessing relationships with relatives. Some articles included patients in the research, but none of them had co-created the data collection tool with patients. Conclusions Our review outlined that few studies considered chronic diseases as a whole and that few patients are involved in the co-construction of data collection tools as well. There is an evidence gap concerning the results in terms of methodological quality when engaging patients in their design. Future research should evaluate why cannabis’ effectiveness varies between patients, and how access affects the decision to use or not to use MC, particularly regarding the relationship between patients and healthcare providers. Future research should consider age and gender while assessing perceptions and should take into consideration the legislation status of cannabis as these factors could in fact shape perception. To reduce stigma and stereotypes about MC users, better quality and accessible information on MC should be disseminated.

show abstract

Self-Efficacy in Researching and Obtaining Medical Cannabis by Patients With Chronic Conditions

Cited by 13 publications

References 20 publications

Patient Experience and Perspective on Medical Cannabis as an Alternative for Musculoskeletal Pain Management

Patient Experience and Perspective on Medical Cannabis as an Alternative for Musculoskeletal Pain Management

Description and Disposition of Patients With Cancer Accessing a Novel, Pharmacist-Led Cannabis Consultation Service

Perceptions and engagement of patients with chronic conditions on the use of medical cannabis: a scoping review

Contact Info

Product

Resources

About